Phacoemulsification vs SLT as Initial Treatment for Pseudoexfoliation Glaucoma
The Canadian Pseudoexfoliation Glaucoma Study 1 is a randomized clinical trial that aims to compare two initial treatment options - Selective Laser Trabeculoplasty (SLT) and Phacoemulsification (PHACO) - in newly diagnosed patients with pseudoexfoliation and need to lower the intraocular pressure. Patients with pseudoe
| Condition(s) | Pseudoexfoliation Glaucoma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The Canadian Pseudoexfoliation Glaucoma Study 1 is a randomized clinical trial that aims to compare two initial treatment options - Selective Laser Trabeculoplasty (SLT) and Phacoemulsification (PHACO) - in newly diagnosed patients with pseudoexfoliation and need to lower the intraocular pressure. Patients with pseudoexfoliation and a recent decision to lower the intraocular pressure, who also have early asymptomatic lens opacification will be recruited and randomized to receive either SLT or PHACO. Patients will be followed for 2 years according to a target IOP protocol based on the Canadian Ophthalmological Society Glaucoma guidelines. Patients who do not achieve the target IOP with the initial randomization procedure will receive IOP lowering medications. The main outcome of interest wi |
| Who can participate | Inclusion Criteria: 1. Pseudoexfoliation syndrome, detected at slit-lamp examination by exfoliative material on anterior capsule, pupil, or anterior chamber angle 2. Clinical decision to lower the IOP, as assessed by the investigator who is treating the subject, based on the presence of PXG or with IOP elevated enough to warrant treatment, even without clear evidence of optic nerve damage or visual field defect 3. Presence of asymptomatic early cataract Exclusion Criteria: 1. Age less than 50 years old 2. Anterior chamber angle closure at gonioscopy, defined as pigmented trabeculum visible in less than 180ยบ 3. Previous IOP lowering procedure such as trabeculoplasty, trabeculectomy, or minimally invasive glaucoma surgery 4. Previous use of IOP lowering medication for more than 6 months 5. P |
| Ages | 50 Years |
| Sex | All |
| Lead sponsor | Nova Scotia Health Authority |
| Locations | Halifax, Nova Scotia, Canada |
| Start date | 2022-10-10 |
| NCT ID | NCT04416724 |
| Official listing | https://clinicaltrials.gov/study/NCT04416724 |